Insmed (INSM)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Insmed (INSM)
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
Key Insights
Critical company metrics and information
Share Price
$75.36Market Cap
$13.48 BillionTotal Outstanding Shares
178.90 Million SharesTotal Employees
912Dividend
No dividendIPO Date
June 1, 2000SIC Description
Pharmaceutical PreparationsHomepage
https://www.insmed.com
Historical Stock Splits
If you bought 1 share of INSM before March 3, 2011, you'd have 0.10 shares today.
| Execution Date | Split Amount |
|---|---|
| March 3, 2011 | 1-for-10 (Reverse Split) |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $-618.72 Million |
| Exchange Gains/Losses | $1.21 Million |
| Net Cash Flow From Operating Activities | $-618.72 Million |
| Net Cash Flow From Investing Activities | $-713.13 Million |
| Net Cash Flow | $-25.66 Million |
| Net Cash Flow From Investing Activities, Continuing | $-713.13 Million |
| Net Cash Flow, Continuing | $-26.87 Million |
| Net Cash Flow From Financing Activities, Continuing | $1.30 Billion |
| Net Cash Flow From Financing Activities | $1.30 Billion |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Gross Profit | $264.92 Million |
| Income/Loss From Continuing Operations After Tax | $-864.28 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-864.28 Million |
| Basic Average Shares | $478.35 Million |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Other Operating Expenses | $535.37 Million |
| Interest Expense, Operating | $84.15 Million |
| Net Income/Loss Attributable To Parent | $-864.28 Million |
| Operating Income/Loss | $-826.11 Million |
| Revenues | $342.96 Million |
| Costs And Expenses | $1.17 Billion |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Income/Loss From Continuing Operations Before Tax | $-860.85 Million |
| Income Tax Expense/Benefit, Deferred | $54000.00 |
| Cost Of Revenue | $78.03 Million |
| Operating Expenses | $1.09 Billion |
| Diluted Average Shares | $478.35 Million |
| Net Income/Loss | $-864.28 Million |
| Diluted Earnings Per Share | $5.55 |
| Benefits Costs and Expenses | $1.20 Billion |
| Research and Development | $555.67 Million |
| Basic Earnings Per Share | $5.55 |
| Income Tax Expense/Benefit | $3.44 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Long-term Debt | $971.76 Million |
| Wages | $55.70 Million |
| Liabilities And Equity | $2.05 Billion |
| Noncurrent Liabilities | $1.31 Billion |
| Other Non-current Liabilities | $338.61 Million |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Other Current Assets | $1.55 Billion |
| Liabilities | $1.57 Billion |
| Other Non-current Assets | $327.86 Million |
| Accounts Payable | $64.95 Million |
| Current Liabilities | $259.19 Million |
| Current Assets | $1.65 Billion |
| Other Current Liabilities | $138.54 Million |
| Equity Attributable To Parent | $483.42 Million |
| Equity | $483.42 Million |
| Fixed Assets | $75.27 Million |
| Noncurrent Assets | $403.13 Million |
| Assets | $2.05 Billion |
| Inventory | $98.47 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.